StocksMedium•13 November 2026•
1 min read
Hims & Hers Partners with Eli Lilly to Offer FDA-Approved Weight-Loss Drugs
Key Facts
1Hims & Hers announced a partnership with Eli Lilly to offer FDA-approved weight-loss drugs including Zepbound.
Hims & Hers announced a partnership with Eli Lilly to offer FDA-approved weight-loss drugs. Zacks reported that the agreement includes providing medications such as Zepbound and Foundayo on the company's platform, aiming to expand patient access to obesity care.
The partnership serves to strengthen the Hims & Hers healthcare platform following recent margin pressures. Shares of Eli Lilly (LLY) were trading at $1440.08704 on November 13, 2026, with a session high of $1441.83.